Morelli Adrian E, Coates P Toby H, Shufesky William J, Barratt-Boyes Simon M, Fung John J, Demetris Anthony J, Thomson Angus W
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Transplantation. 2007 Mar 15;83(5):656-62. doi: 10.1097/01.tp.0000255320.00061.e9.
Hematopoietic growth factors (HGF) mobilize potential tolerogenic cells in transplant donors. Fms-like tyrosine kinase 3 ligand (Flt3L) mobilizes stem cells and dendritic cells (DCs) in human and nonhuman primate blood. Blood and renal and liver biopsies were obtained from untreated and Flt3L-mobilized rhesus macaques. Flt3L increased the number of myeloid CD11c(hi) and plasmacytoid CD123(hi) precursors in blood and both myeloid CD11c(+) HLA-DR(+) fascin(+) (CD45RA(-)) DCs and putative plasmacytoid CD11c(lo) CD45RA(hi) DC precursors in liver and kidneys, without affecting organ function. DC in Flt3L-treated monkeys were concentrated in the glomeruli and interstitium of kidneys, and in the portal triads and parenchyma of liver. These DCs exhibited the phenotype of immature antigen-presenting cells (APCs; CD83(-) CD86(lo) CCR5(+) CCR7(-)). HGF-induced changes reversed significantly within 7 days of Flt3L withdrawal. Therapeutic protocols that mobilize donor hematopoietic cells should consider the influence of HGF on the APC constituency of prospective organ allografts.
造血生长因子(HGF)可动员移植供体中的潜在致耐受性细胞。Fms样酪氨酸激酶3配体(Flt3L)可动员人类和非人类灵长类动物血液中的干细胞和树突状细胞(DC)。从未经治疗和经Flt3L动员的恒河猴获取血液、肾脏和肝脏活检样本。Flt3L增加了血液中髓样CD11c(高)和浆细胞样CD123(高)前体细胞的数量,以及肝脏和肾脏中髓样CD11c(+) HLA-DR(+) fascin(+)(CD45RA(-))DC和假定的浆细胞样CD11c(低) CD45RA(高) DC前体细胞的数量,且不影响器官功能。Flt3L处理的猴子体内的DC集中在肾脏的肾小球和间质以及肝脏的门三联体和实质中。这些DC表现出未成熟抗原呈递细胞(APC;CD83(-) CD86(低) CCR5(+) CCR7(-))的表型。在停用Flt3L后7天内,HGF诱导的变化显著逆转。动员供体造血细胞的治疗方案应考虑HGF对预期器官同种异体移植物APC组成的影响。